(AOF) – LNA Santé announces stable net profit group share in the first half at 14.3 million euros, for a turnover up 6.7% to 357 million euros compared to 334.5 million one year ago. Ebitda increased by 2.1% to 71.2 million. For 2023, the retirement home group confirms its activity forecast by targeting organic growth of 6% and an operating turnover close to 720 million euros. Operating leverage, which represents the ratio of net operating financial debt to Ebitda, should remain below a ratio of 2.
“Free cash flows generated in the first half of 2023 amounted to 23.2 million euros and increased by 10% year-on-year thanks to the generation of solid EBITDA and the disbursement of a lower operating expense. tax”.
“EHPADs display an average occupancy rate of 93.7% over the first half of the year, an improvement of 0.5 points compared to the first half of 2022” while “over the second quarter, they increased by 0.4 points per year”. compared to the previous quarter” notes the group.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.